CN105745208A - 一种抗感染化合物 - Google Patents

一种抗感染化合物 Download PDF

Info

Publication number
CN105745208A
CN105745208A CN201480054331.1A CN201480054331A CN105745208A CN 105745208 A CN105745208 A CN 105745208A CN 201480054331 A CN201480054331 A CN 201480054331A CN 105745208 A CN105745208 A CN 105745208A
Authority
CN
China
Prior art keywords
chloro
ethyl
hydrogen
methyl
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480054331.1A
Other languages
English (en)
Chinese (zh)
Inventor
金在昇
姜善姬
徐敏俊
徐沐杨
徐姜铮
李世密
康居姬
东斯克·帕克
金阮优
凯文·匹斯
南克漾
金姜俊
欧素云
李塞岩
安基晔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur Korea
Qurient Co Ltd
Original Assignee
Institut Pasteur Korea
Qurient Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur Korea, Qurient Co Ltd filed Critical Institut Pasteur Korea
Priority to CN201811384685.9A priority Critical patent/CN109575018A/zh
Publication of CN105745208A publication Critical patent/CN105745208A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480054331.1A 2013-08-02 2014-08-01 一种抗感染化合物 Pending CN105745208A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811384685.9A CN109575018A (zh) 2013-08-02 2014-08-01 一种抗感染化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361861750P 2013-08-02 2013-08-02
US61/861,750 2013-08-02
PCT/EP2014/066614 WO2015014993A2 (en) 2013-08-02 2014-08-01 Anti-infective compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811384685.9A Division CN109575018A (zh) 2013-08-02 2014-08-01 一种抗感染化合物

Publications (1)

Publication Number Publication Date
CN105745208A true CN105745208A (zh) 2016-07-06

Family

ID=51260879

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480054331.1A Pending CN105745208A (zh) 2013-08-02 2014-08-01 一种抗感染化合物
CN201811384685.9A Pending CN109575018A (zh) 2013-08-02 2014-08-01 一种抗感染化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811384685.9A Pending CN109575018A (zh) 2013-08-02 2014-08-01 一种抗感染化合物

Country Status (12)

Country Link
US (1) US20160185774A1 (enExample)
EP (1) EP3027615B1 (enExample)
JP (3) JP2016525562A (enExample)
KR (1) KR102292293B1 (enExample)
CN (2) CN105745208A (enExample)
DK (1) DK3027615T3 (enExample)
ES (1) ES2883565T3 (enExample)
HU (1) HUE056198T2 (enExample)
PH (1) PH12016500207A1 (enExample)
RU (1) RU2734760C2 (enExample)
SG (1) SG11201600686QA (enExample)
WO (1) WO2015014993A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101828A (zh) * 2018-01-15 2018-06-01 西华师范大学 3-吲哚基甲酰胺类化合物及其制备方法
WO2019148575A1 (zh) * 2018-02-01 2019-08-08 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
CN115093408A (zh) * 2019-09-10 2022-09-23 盐野义制药株式会社 可用于抗分枝杆菌感染的含有苄胺的5,6-杂芳族化合物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3316969T2 (ro) * 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
PE20181352A1 (es) * 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
EP3472152A1 (en) * 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN111246848A (zh) 2017-10-05 2020-06-05 快尔生物技术公司 与抗结核药物组合的环稠和的噻唑并2-吡啶酮
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
CN114423758B (zh) * 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
KR20220071199A (ko) * 2019-09-30 2022-05-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 4-퀴놀리논 항균 화합물
CA3151712A1 (en) * 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
IL328855A (en) 2019-12-20 2026-08-01 Qurient Co Ltd Q203 Pharmaceutical Oral Dosage Form
KR102381397B1 (ko) * 2020-07-10 2022-03-30 경희대학교 산학협력단 신규 나프토퀴논 유도체 화합물 및 이를 포함하는 항균용 조성물
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
JP2025530847A (ja) * 2022-09-16 2025-09-17 北京華益健康薬物研究中心 Ｍｅｔｔｌ３阻害剤化合物、その医薬組成物及び用途
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
JP2026525955A (ja) 2023-07-18 2026-08-04 ヤンセン ファーマシューティカ エヌ．ベー． ベダキリン、プレトマニド又はデラマニド、及びシトクロムｂｃ１阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用
CN117946118A (zh) * 2024-01-15 2024-04-30 珃诺生物医药科技(杭州)有限公司 一种靶向降解erk5蛋白的化合物及其制备方法
CN119118959A (zh) * 2024-09-06 2024-12-13 镇江市高等专科学校 4-[4-(氨基甲基)苯基]哌嗪-1-羧酸叔丁酯的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057145A2 (en) * 2009-11-05 2011-05-12 University Of Notre Dame Du Lac Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same
WO2012143796A2 (en) * 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
CN102869661A (zh) * 2010-03-18 2013-01-09 韩国巴斯德研究所 抗感染化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
CA2672960A1 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2009140101A2 (en) * 2008-05-12 2009-11-19 Boehringer Ingelheim International Gmbh Imidazopyridine compounds useful as mmp-13 inhibitors
CN103324035B (zh) * 2013-06-20 2015-07-01 深圳市华星光电技术有限公司 掩膜板和阵列基板的制作方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057145A2 (en) * 2009-11-05 2011-05-12 University Of Notre Dame Du Lac Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same
CN102869661A (zh) * 2010-03-18 2013-01-09 韩国巴斯德研究所 抗感染化合物
WO2012143796A2 (en) * 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101828A (zh) * 2018-01-15 2018-06-01 西华师范大学 3-吲哚基甲酰胺类化合物及其制备方法
CN108101828B (zh) * 2018-01-15 2021-05-04 西华师范大学 3-吲哚基甲酰胺类化合物及其制备方法
WO2019148575A1 (zh) * 2018-02-01 2019-08-08 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
CN115093408A (zh) * 2019-09-10 2022-09-23 盐野义制药株式会社 可用于抗分枝杆菌感染的含有苄胺的5,6-杂芳族化合物
CN115093408B (zh) * 2019-09-10 2025-03-11 盐野义制药株式会社 可用于抗分枝杆菌感染的含有苄胺的5,6-杂芳族化合物

Also Published As

Publication number Publication date
RU2016107378A (ru) 2017-09-07
JP2016525562A (ja) 2016-08-25
WO2015014993A3 (en) 2015-04-02
JP2018158941A (ja) 2018-10-11
SG11201600686QA (en) 2016-02-26
EP3027615A2 (en) 2016-06-08
HUE056198T2 (hu) 2022-02-28
PH12016500207A1 (en) 2016-04-25
KR20170082450A (ko) 2017-07-14
EP3027615B1 (en) 2021-07-21
ES2883565T3 (es) 2021-12-09
JP2019131606A (ja) 2019-08-08
CN109575018A (zh) 2019-04-05
JP6757768B2 (ja) 2020-09-23
RU2016107378A3 (enExample) 2018-03-29
KR102292293B1 (ko) 2021-08-23
WO2015014993A2 (en) 2015-02-05
DK3027615T3 (da) 2021-10-25
US20160185774A1 (en) 2016-06-30
RU2734760C2 (ru) 2020-10-23

Similar Documents

Publication Publication Date Title
JP6757768B2 (ja) 抗感染症化合物
CN113527293B (zh) Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途
CN112752756B (zh) 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TWI338684B (en) Tetrahydroquinoline derivatives and a process for preparing the same
KR102153886B1 (ko) Atr 키나제 억제제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물, 이의 제조 방법, 이의 상이한 고체형 및 방사성표지된 유도체
TW202140448A (zh) 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
KR101496273B1 (ko) 1,7-디아자카르바졸 및 암 치료에서의 그 용도
TWI781607B (zh) 一種免疫抑制劑、其製備方法和應用
CN106573906A (zh) 哌啶‑二酮衍生物
WO2021115457A1 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN106573915A (zh) 针对布罗莫结构域有活性的化合物
CN104010639A (zh) 作为RORγt调节剂的酰胺类化合物及其应用
WO2024017384A1 (zh) 恢复p53突变功能的化合物及其应用
TW202142541A (zh) 用作激酶抑制劑的化合物及其應用
CN108349947A (zh) 四氢吲唑及其医药用途
CN117384165A (zh) 一种用于egfr蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CN114929685B (zh) 稠合吡啶环衍生物、其制备方法及其在医药上的应用
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2023160475A1 (zh) 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
WO2025162254A1 (zh) 包含三并环的化合物
WO2025195363A1 (zh) 包含内酰胺结构的化合物
HK40103536A (en) Chromene derivatives as inhibitors of tcr-nck interaction
HK40115101A (en) Quinoline compounds as inhibitors of kras
HK40105522A (en) Parp1 inhibitors and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160706

RJ01 Rejection of invention patent application after publication